LISD: Lifestyle Intervention for Senior Diabetics

Sponsor
Baylor College of Medicine (Other)
Overall Status
Completed
CT.gov ID
NCT02348801
Collaborator
American Diabetes Association (Other), Michael E. DeBakey VA Medical Center (U.S. Fed), Biomedical Research Institute of New Mexico (Other)
100
1
2
72
1.4

Study Details

Study Description

Brief Summary

Older people with diabetes will be assigned to the 1-year lifestyle program or no lifestyle program while continuing usual treatment for diabetes. The lifestyle program will consist of teaching how to practice healthy diet and regular exercise at our facility and continued into the community and home. It is hoped that the results would provide convincing proof about the usefulness of lifestyle change in older patients with diabetes.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Weight loss and Exercise
  • Behavioral: Healthy lifestyle
N/A

Detailed Description

Background: Hypothesis: Lifestyle intervention will be highly successful in the population of older adults with diabetes, with resultant significant improvement in glycemic metabolic control mediated by improved insulin action/secretion, accompanied by significant improvements in physical function, cognitive function, and quality-of-life (QOL).

Rationale: Countering the prevailing notion that it is difficult to change lifelong habits, the PI has ample preliminary data showing successful lifestyle change in older adults. A similar lifestyle intervention augmented by motivational interviewing might also be successful in older adults with diabetes with eventual translation to the community- and home-settings.

Aims: In older adults with diabetes and comorbidities, the aims are to: determine the effect of lifestyle intervention on glycemic metabolic control, determine the mechanisms underlying lifestyle-induced changes in glucose homeostasis, and determine the effect of lifestyle intervention on age-relevant health outcomes: physical function, cognitive function, QOL.

Design: Older adults with diabetes and comorbidities will be randomized to center-based lifestyle intervention continued into the community and home vs. healthy-lifestyle control for 1 year.

Relevance to diabetes prevention and treatment: Data from a randomized-controlled trial will provide high-level evidence to convince practitioners to implement lifestyle intervention as the primary therapy for diabetes in older patients.

Study Design

Study Type:
Interventional
Actual Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Lifestyle Intervention Strategy to Treat Diabetes in Older Adults
Study Start Date :
Jan 1, 2015
Actual Primary Completion Date :
Dec 1, 2018
Actual Study Completion Date :
Dec 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Healthy Lifestyle Group

Group diabetes educations sessions that focus on diet, exercise, and social support.

Behavioral: Healthy lifestyle
Diabetes support and education

Experimental: Weight Loss plus Exercise Group

Behavioral therapy for weight loss and exercise training

Behavioral: Weight loss and Exercise
Group behavior therapy sessions designed to acquire positive weight-control skills and attitudes, and practice weight-maintenance skills. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement. Exercise sessions of ~90 min duration 15 min warm-up of flexibility exercise, followed by ~30 min of aerobic exercise, and, after a brief rest period, ~30 min of resistance training, and finally ~15 min balance exercise) conducted three times weekly supervised at our exercise facility for first six months, and regular exercises continued at community-fitness centers and at home for the following six months.

Outcome Measures

Primary Outcome Measures

  1. Change in hemoglobin A1c [baseline and 12 months]

Secondary Outcome Measures

  1. Change in insulin sensitivity [baseline and 12 months]

  2. Change in insulin secretion [baseline and 12 months]

  3. Change in fasting glucose [baseline and 12 months]

  4. Change in adipocytokines and hormones [baseline and 12 months]

  5. Change in peak aerobic power [baseline and 12 months]

  6. Change in cardiometabolic risk profile [baseline and 12 months]

  7. Change in the modified physical performance test [baseline and 12 months]

  8. Change in composite cognitive z-score [baseline and 12 months]

  9. Change in quality of life [baseline and 12 months]

  10. Change in health care utilization [baseline and 12 months]

  11. Change in the modified mini-mental state exam [baseline and six months]

  12. Change in muscle strength and quality [baseline and 12 months]

  13. Change in gait speed [baseline and 12 months]

  14. Change in stroop color naming [baseline and 12 months]

  15. Change in word list fluency [baseline and 12 months]

  16. Change in ray auditory verbal learning test [baseline and 12 months]

  17. Change in Trail A./B [baseline and 12 months]

  18. Change in Lean body mass [baseline and 12 months]

  19. Change in fat mass and visceral fat [baseline and 12 months]

  20. Change in bone mineral density [baseline and 12 months]

  21. Change in bone metabolism [baseline and 12 months]

  22. Change in bone quality [baseline and 12 months]

  23. Change in composite cognitive score [baseline and 12 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subjects will be older (age 65-85 years) adults with type 2 diabetes. Diabetes will be determined by self-report with verification (medical records, current treatment, confirmation from health care provider, fasting glucose ≥126 mg/dL, symptoms of hyperglycemia with plasma glucose ≥200 mg/dL or 2-hour plasma glucose ≥200 mg/dL after a 75-g glucose load on at least two occasions, or HbA1C of ≥ 6.5%. All subjects will have a BMI of ≥ 27 kg/m2 and have stable weight (±2 kg) and on stable medications during the last 6 mos.
Exclusion Criteria:
  • Volunteers will be excluded if they fail to provide informed consent, have any major comorbid disease that is uncontrolled, or any condition that is likely to limit life span and/or affect the safety of the interventions, or interfere with the conduct of the trial. Examples include: 1) unstable cardiopulmonary disease (e.g. recent MI, unstable angina, stroke within past 3 months) or unstable disease (e.g. Class IV congestive heart failure: 2) severe orthopedic (e.g. awaiting joint replacement) and/or neuromuscular (e.g. multiple sclerosis, amyotrophic lateral sclerosis, active rheumatoid arthritis), 3) significant cognitive impairment, defined as a known diagnosis of dementia or positive screening test for dementia using the Mini-Mental State exam (i.e. MMSE score <24),43 4) cancer requiring treatment in the past 5 years,
  1. documented history of pulmonary embolism in the past 6 months, 6) positive exercise stress test for cardiac ischemia, and 7) HbA1c >11%.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Michael E DeBakey VA Medical Center Houston Texas United States 77030

Sponsors and Collaborators

  • Baylor College of Medicine
  • American Diabetes Association
  • Michael E. DeBakey VA Medical Center
  • Biomedical Research Institute of New Mexico

Investigators

  • Principal Investigator: Dennis T Villareal, MD, Baylor College of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dennis T. Villareal, Professor of Medicine, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT02348801
Other Study ID Numbers:
  • H-34800
First Posted:
Jan 28, 2015
Last Update Posted:
Jan 14, 2021
Last Verified:
Jan 1, 2021
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 14, 2021